In a phase 3 trial for patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy, T-Dxd has been shown to yield a survival benefit in patients with HER2-low advanced breast cancer compared to the physician’s choice of chemotherapy [44]. Here, ERBB2 is linked to breast cancer.